Omada Health Competitive Intelligence & Landscape
omadahealth.com ·
Overview
Omada Health Overview
The company's core products include digital health programs focused on conditions such as diabetes, hypertension, and obesity, providing personalized support, coaching, and behavioral interventions via digital platforms. These services are targeted primarily at employers, health plans, and healthcare providers seeking scalable, evidence-based solutions to chronic disease management (CNBC).
Omada's mission is to bend the curve of chronic disease, emphasizing long-term health improvements and sustainable lifestyle changes. The company’s value proposition centers on delivering impactful, accessible, and cost-effective care that addresses a significant global health challenge, reflecting its commitment to innovation and impact in healthcare (Omada Health). As a private company until its 2025 IPO, Omada has grown significantly, positioning itself as a leader in digital health solutions for chronic disease prevention and management.
Omada Health Weekly Intel Updates
Receive weekly intel updates about Omada Health straight to your inbox.
Competitors
Omada Health Competitors
Virta Health stands out with its focus on reversing type 2 diabetes through a medically supervised ketogenic diet, emphasizing a more intensive, clinical approach compared to Omada’s behavioral and educational strategies. Virta’s market positioning targets patients seeking a more aggressive intervention, and it is gaining traction for its evidence-based results (mantra.care).
Livongo, now part of Teladoc Health, is another major competitor, offering a platform that combines connected devices, real-time coaching, and data analytics to improve management of diabetes, hypertension, and other chronic conditions. Its key differentiator is its focus on real-time data and personalized coaching, with a strong market share driven by Teladoc’s extensive telehealth network (mantra.care).
Big Health specializes in digital mental health solutions, providing evidence-based cognitive behavioral therapy (CBT) programs for conditions like insomnia and anxiety. While not directly competing in the chronic condition management space, its market positioning as a mental health leader complements Omada’s broader health management ecosystem (CB Insights).
Hinge Health focuses on musculoskeletal health, offering digital therapy and remote monitoring for chronic pain management. Its differentiation lies in its specialized, clinically validated programs and integration with wearable devices, positioning itself as a leader in digital musculoskeletal care, which complements Omada’s chronic disease management offerings (CB Insights).
Sources
Top 10 Omada Platform Alternatives & Competitors - AVIA Marketplace
marketplace.aviahealth.com
Best Omada Health Alternatives for Diabetes & Chronic Care
mantra.care
Best Omada Alternatives & Competitors - SourceForge
sourceforge.net
Top Omada Health Alternatives, Competitors - CB Insights
cbinsights.com
Omada Health (OMDA): Investment Thesis Explained
mvcinvesting.substack.com
Health care competition, strategic mission, and patient satisfaction
pmc.ncbi.nlm.nih.gov
Product & Pricing
Omada Health Product and Pricing Intelligence
While specific tiered pricing details and exact costs are not publicly disclosed, Omada emphasizes cost savings, with reported benefits such as an average of $2,948 in gross cost savings per member at year two for multi-condition programs like diabetes and hypertension (Omada Platform). The platform includes features like personalized health coaching, connected devices, and tailored care plans, which are included as part of their integrated service offering rather than as separate paid features.
Recent updates highlight their success in reducing healthcare utilization and costs, especially through virtual physical therapy programs for musculoskeletal conditions, which have demonstrated lower costs compared to traditional in-person therapy (News Release). Overall, Omada’s pricing model is designed to be flexible and outcome-driven, aligning costs with the value delivered through improved health outcomes and long-term savings.
Ad Campaigns
Omada Health Ad Campaigns
Omada Health is currently running 573 ads across Google, LinkedIn — 16 on Google and 557 on LinkedIn. Explore Omada Health's live ad creative, messaging, and the platforms they advertise on in the ad library — updated automatically by ForesightIQ.
See of Omada Health's ads
Browse the live creative across Google, Meta & LinkedIn in the ad library
Hiring & Layoffs
Omada Health Hiring and Layoffs
In terms of layoffs, there is no recent publicly available information indicating significant workforce reductions at Omada Health, suggesting the company is maintaining or even increasing its workforce to support growth initiatives. Their financial results for Q2 2025 reveal robust revenue growth and progress toward profitability, which typically correlates with stable or expanding staffing levels (Omada Health Q2 2025 results).
Overall, Omada Health’s hiring patterns signal a strategic focus on innovation, technology integration, and scaling their healthcare programs. The company’s emphasis on AI, new product launches like OmadaSpark, and expanding member support through partnerships with major pharmacy benefit managers indicate a forward-looking strategy aimed at consolidating their position in the digital health space.
Sources
Careers - Omada Health
omadahealth.com
Omada Health Reports Second Quarter 2025 Results
omadahealth.com
Remote Senior Software Engineer at Omada Health
remoteok.com
Omada Health - Great Place To Work
greatplacetowork.com
Omada Health INC -- H1B Data - Salaries, Approvals, LCAs
h1bgrader.com
Healthcare Moves: A Monthly Summary of Hires, Exits and ...
medcitynews.com
Leadership
Omada Health Management and Leadership Team
In recent developments, Omada Health has expanded its governance with notable additions to its Board of Directors, including Sachin Jain, M.D., MBA, Julie Klapstein, and Adam Stavisky in 2024. These board members bring extensive clinical and commercial expertise, with Jain recognized for his leadership in healthcare innovation, Klapstein for her strategic roles, and Stavisky for his experience in benefits management at Walmart (Business Wire).
Furthermore, Omada has strengthened its clinical advisory board with industry leaders such as Ellen Beckjord, Lisa Fitzpatrick, Prachi Nagda, and Geeta Nayyar, who provide expert guidance on clinical services and population health initiatives. These strategic leadership and advisory appointments underscore Omada's commitment to clinical excellence and innovation in digital health (Omada Health News Release).
Financials
Omada Health Financial Performance, Fundraising, M&A
Fundraising details indicate that Omada has secured substantial funding rounds, although specific figures and valuations are not detailed in the available sources. The company has also made notable strides in profitability, reporting its first GAAP profitable quarter recently, alongside improved margins and positive net income in the fourth quarter of 2025 (simplywall.st). Additionally, Omada launched the GLP-1 Flex Care program, expanding its offerings in anti-obesity medications, which signals ongoing strategic growth and innovation (investors.omadahealth.com). There are no publicly available details on recent M&A activity or specific valuation figures, but the company's recent financial performance and strategic initiatives suggest a positive outlook for its financial health.
Sources
[PDF] Omada Health Reports Fourth Quarter and Full-Year 2025 Results
investors.omadahealth.com
[PDF] Q4 2025 Omada Health Inc Earnings Call on March 05, 2026 / 9:30PM
investors.omadahealth.com
Omada Health (OMDA) Valuation Check As GAAP Profitability And ...
simplywall.st
Omada Health Reports Preliminary, Unaudited Revenue for the ...
investors.omadahealth.com
Omada Health Reports Second Quarter 2025 Results
omadahealth.gcs-web.com
Omada Health Reports Fourth Quarter and Full-Year 2025 Results
finance.yahoo.com
Partnerships
Omada Health Partnerships, Clients and Vendors
In terms of enterprise clients, Omada serves a wide range of health plans and employers, providing evidence-based programs that focus on population health management, health equity, and cost reduction (Omada for Health Plans) and (Omada for Employers). The company also collaborates with tech giants like Amazon, integrating its programs into Amazon’s Health Condition Programs to increase awareness and enrollment among millions of eligible members, further expanding its reach (Amazon partnership).
Omada’s vendor ecosystem includes physical therapy groups like Physera Physical Therapy Group, with whom it partners to deliver comprehensive care, and technology providers that enable real-time data exchange via APIs and Single Sign-On (SSO) integrations. These relationships facilitate seamless program delivery and personalized member experiences, supporting Omada’s mission to reverse chronic disease costs at scale (Omada on Castlight). Overall, Omada’s ecosystem reflects a strategic blend of healthcare, technology, and corporate partners committed to innovative, scalable virtual health solutions.
Sources
Who We Serve | Health Plans - Omada Health
omadahealth.com
Who We Serve | Employers - Omada Health
omadahealth.com
AMA, Omada, Intermountain Healthcare partner against type 2 ...
ama-assn.org
Omada - Castlight Health
castlighthealth.com
Omada Health Joins Amazon's Health Condition Programs as ...
omadahealth.com
Virtual Care Innovation & Research | Omada Health
omadahealth.com
Amazon launches health monitoring program, partners with Omada ...
finance.yahoo.com
Events
Omada Health Event Participations
Sources
Events | Omada Health, Inc.
investors.omadahealth.com
Omada Health: Manage Chronic Conditions & Embrace Your Health
omadahealth.com
Omada Horizon Day - The Food Experience 2025
omadahealth.com
Omada Health to Participate in Upcoming Investor Conference
investors.omadahealth.com
[PDF] Q4 2025 Omada Health Inc Earnings Call on March 05, 2026 / 9:30PM
investors.omadahealth.com
Omada Health to Announce Fourth Quarter and Full Year 2025 ...
investors.omadahealth.com
Frequently Asked Questions
What does Omada Health's 53% revenue growth in 2025 and first GAAP-profitable quarter signal — genuine inflection or a one-time pop?
The evidence points toward a genuine inflection rather than a one-time event. Omada reported full-year 2025 revenue of approximately $260 million (up 53% year-over-year), Q4 2025 revenue of roughly $76 million (up 58% YoY), and membership of ~886,000 (up 55% YoY) — all accelerating together. Achieving its first GAAP-profitable quarter alongside that top-line growth and a 2025 IPO suggests the business has crossed a meaningful operating-leverage threshold, though sustained profitability across multiple quarters will be the real test.
What does Omada's hiring concentration in senior software engineering and AI roles indicate about where the product is headed?
Omada's current hiring pattern — with notable emphasis on senior software engineers and AI-related roles — suggests the company is deepening its technology layer rather than simply scaling headcount for program delivery. Combined with product launches like OmadaSpark and the GLP-1 Flex Care program, this signals a roadmap focused on intelligent, personalized care automation. The absence of reported layoffs alongside robust Q2 2025 revenue growth implies this engineering build-out is funded by operating momentum rather than a pivot born of distress.
What does Omada's partnership with Amazon's Health Condition Programs signal about its go-to-market strategy?
The Amazon partnership marks a significant channel shift: rather than relying exclusively on direct employer and health-plan sales, Omada is embedding itself inside consumer distribution infrastructure that reaches millions of eligible members at enrollment. This is a distribution-scale bet — Amazon surfaces Omada to employees and Prime members who might never have encountered it through a traditional benefits broker. For competitive-intelligence purposes, it suggests Omada is trying to reduce customer-acquisition costs and accelerate member growth by piggybacking on Amazon's existing health platform rather than fighting purely on enterprise RFP cycles.
How does Omada's enrollment-based, outcomes-linked pricing model position it competitively against fee-for-service digital health rivals?
Omada's model — billing through medical claims only when members enroll, and anchoring value on measurable savings (reported at $2,948 gross cost savings per member at year two for multi-condition programs) — removes the upfront risk that makes CFOs and benefits buyers hesitant to commit to digital health vendors. Competitors like Welldoc and Glooko that rely more on platform licensing or per-device fees face a harder commercial conversation in an environment where payers demand demonstrated ROI. This pricing architecture is a structural advantage in health-plan and large-employer sales cycles, though it also exposes Omada to revenue variability if enrollment rates disappoint.
What signal does the addition of Adam Stavisky — a Walmart benefits veteran — to Omada's board send about its enterprise sales ambitions?
Stavisky's appointment in 2024 is a deliberate credentialing move for the large self-insured employer segment. Walmart is one of the most scrutinized corporate benefits programs in the U.S., and having its former benefits executive on the board gives Omada a direct proxy for how mega-employers evaluate and deploy health programs at scale. Paired with Sachin Jain (clinical innovation credibility) and Julie Klapstein (strategic/operational background), the board composition reads as preparation for both deeper enterprise penetration and the investor scrutiny that accompanies a post-IPO public company.
Does Omada's launch of the GLP-1 Flex Care program represent a defensive move against Virta Health and weight-management competitors, or a genuine new growth vector?
It is likely both. GLP-1 medications have rapidly become the dominant conversation in obesity and metabolic health, and Virta Health's medically supervised model and Teladoc/Livongo's scale made it urgent for Omada to have a credible anti-obesity medication offering. By launching GLP-1 Flex Care, Omada extends its behavioral-change platform into medication management rather than ceding that member cohort to rivals. Given that Omada's existing infrastructure — coaching, connected devices, claims billing — can wrap around GLP-1 adherence and side-effect management, this also represents a realistic revenue expansion opportunity rather than a feature built purely for defensive optics.
What does Omada's attendance at J.P. Morgan Healthcare, Evercore, and Morgan Stanley healthcare conferences in 2025–2026 indicate about its investor-relations posture post-IPO?
The concentration of appearances at the three most influential healthcare investor conferences — J.P. Morgan (January 2026), Evercore (December 2025), and Morgan Stanley (September 2025) — is a deliberate institutional investor cultivation strategy typical of a company in the first 12–18 months after going public. Omada's senior management presenting at all three suggests the company is actively managing its equity story, building sell-side relationships, and establishing itself as a durable public-market name rather than a one-quarter wonder. For corp-dev and strategy observers, it also signals management bandwidth is being allocated to capital-markets positioning alongside operational execution.
How does Omada's multi-condition program design (diabetes + hypertension bundled) create competitive moat against single-condition point solutions?
Omada's integrated multi-condition platform creates switching costs and network effects that single-condition point solutions like Virta Health (type 2 diabetes reversal only) or Glooko (diabetes data integration) cannot easily replicate. Employers and health plans managing populations with high comorbidity rates — diabetes and hypertension frequently co-occur — benefit from consolidated contracting, a single member experience, and unified reporting. The reported $2,948 gross cost savings per member at year two for multi-condition programs gives buyers a combined ROI figure that individual point solutions struggle to match when aggregated across a benefits stack. This bundling logic also makes Omada harder to displace once it is embedded in an employer's ecosystem.
What does the clinical advisory board expansion — with figures like Ellen Beckjord and Geeta Nayyar — signal about Omada's evidence-generation strategy?
Adding population-health and health-equity specialists to the clinical advisory board suggests Omada is investing in the research and validation infrastructure needed to win health-plan contracts and withstand increasing regulatory and payer scrutiny of digital health outcomes claims. Health-plan buyers increasingly require peer-reviewed evidence and equity-focused outcome data, not just vendor-reported metrics. This advisory expansion is a strategic signal that Omada expects evidence generation — not just program delivery — to be a differentiator in RFP competitions over the next two to three years.
With membership at ~886,000 and revenue at ~$260 million for 2025, what does Omada's implied revenue per member suggest about its pricing power versus peers?
Omada's implied revenue per member for 2025 is approximately $293 annually, which reflects its enrollment-based billing model where revenue accrues across active, engaged members rather than the full addressable population. This per-member figure is a meaningful benchmark when comparing against Teladoc/Livongo's chronic care economics or Hinge Health's musculoskeletal per-episode pricing. If Omada's GLP-1 Flex Care and multi-condition expansion drive higher-acuity members into the platform, revenue per member could rise materially — which is the key financial leverage point in the bull case for the stock.
What does Omada's sponsorship of the Health Evolution Summit and Sales Advantage Summit signal about where it is prioritizing relationship-building?
Sponsoring the Health Evolution Summit (a C-suite healthcare executive forum) and the Sales Advantage Summit (a commercial/go-to-market-oriented event) in the same cycle reveals a two-track influence strategy: cultivating buy-in from health system and payer executives at the top of the decision chain while simultaneously investing in the sales enablement and channel-partnership relationships that drive actual contract volumes. This dual investment is consistent with a post-IPO company that needs to simultaneously build brand equity with senior buyers and accelerate pipeline velocity through distribution partners.
Does Omada's competitive position look more vulnerable from below (emerging point solutions) or from above (Teladoc/Livongo scale), and what does its current strategy imply about which threat it is prioritizing?
Omada's strategy suggests it views the scale threat from Teladoc/Livongo as the more pressing competitive risk, and is responding with multi-condition bundling, GLP-1 integration, and high-profile partnerships (Amazon, AMA, Intermountain) designed to match Teladoc's distribution breadth without requiring a comparable telehealth network. The emerging point-solution threat from companies like Virta Health is being addressed by expanding Omada's condition coverage and clinical credentialing rather than competing on any single condition's clinical depth. Teladoc's integrated platform and existing payer relationships remain the most direct competitive overhang — Omada's IPO and continued revenue acceleration are, in part, about closing that scale gap before Teladoc can leverage its network effects more aggressively in the chronic care segment.
Powered by ForesightIQ · Competitive intelligence from digital exhaust